The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice

Tirzepatide is a dual GIP and GLP-1 receptor co-agonist which is approved for glucose-lowering therapy in type 2 diabetes. Here, we explored its effects on beta cell function, insulin sensitivity and insulin-independent glucose elimination (glucose effectiveness) in normal mice. Anesthetized female C57/BL/6 J mice were injected intravenously with saline or glucose (0.125, 0.35 or 0.75 g/kg) with or without simultaneous administration of synthetic tirzepatide (3 nmol/kg). Samples were taken at 0, 1, 5, 10, 20 and 50 min. Glucose elimination rate was estimated by the percentage reduction in glucose from min 5 to min 20 (K-G). The 50 min areas under the curve (AUC) for insulin and glucose were determined. Beta cell function was assessed as AUC(insulin) divided by AUC(glucose). Insulin sensitivity (S-I) and glucose effectiveness (S-G) were determined by minimal model analysis of the insulin and glucose data. Tirzepatide glucose-dependently reduced glucose levels and increased insulin levels. The slope for the regression of AUC(insulin) versus AUC(glucose) was increased 7-fold by tirzepatide from 0.014 +/- 0.004 with glucose only to 0.099 +/- 0.016 (P < 0.001). S(I )was not affected by tirzepatide, whereas S-G was increased by 78% (P < 0.001). The increase in S-G contributed to an increase in K-G by 74 +/- 4% after glucose alone and by 67 +/- 8% after glucose+ tirzepatide, whereas contribution by S-I times AUC(insulin) insulin (i.e., disposition index) was 26 +/- 4% and 33 +/- 8%, respectively. In conclusion, tirzepatide stimulates both insulin secretion and glucose effectiveness, with stimulation of glucose effectiveness being the prominent process to reduce glucose.

Automated summary

Tirzepatide stimulates both insulin secretion and glucose effectiveness, with stimulation of glucose effectiveness being the prominent process to reduce glucose.